Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico.
Addiction
HIV
Harm reduction
Law enforcement
People who use drugs
Police
Referral
Syringe service program
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
26 07 2021
26 07 2021
Historique:
received:
26
04
2021
accepted:
08
06
2021
entrez:
27
7
2021
pubmed:
28
7
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Police constitute a structural determinant of health and HIV risk of people who inject drugs (PWID), and negative encounters with law enforcement present significant barriers to PWID access to harm reduction services. Conversely, police may facilitate access via officer-led referrals, potentiating prevention of HIV, overdose, and drug-related harms. We aimed to identify police characteristics associated with support for officer-led referrals to addiction treatment services and syringe service programs (SSP). We hypothesized that officers who believe harm reduction services are contradictory to policing priorities in terms of safety and crime reduction will be less likely to support police referrals. Between January and June 2018, police officers (n = 305) in Tijuana, Mexico, completed self-administered surveys about referrals to harm reduction services during the 24-month follow-up visit as part of the SHIELD police training and longitudinal cohort study. Log-binomial regression was used to estimate adjusted prevalence ratios and model policing characteristics and attitudes related to officers' support for including addiction treatment and SSP in referrals. Respondents were primarily male (89%), patrol officers (86%) with a median age of 38 years (IQR 33-43). Overall, 89% endorsed referral to addiction services, whereas 53% endorsed SSP as acceptable targets of referrals. Officers endorsing addiction services were less likely to be assigned to high drug use districts (adjusted prevalence ratio [APR] = 0.50, 95% CI 0.24, 1.08) and more likely to agree that methadone programs reduce crime (APR = 4.66, 95% CI 2.05, 9.18) than officers who did not support addiction services. Officers endorsing SSPs were younger (adjusted prevalence ratio [APR] = 0.96 95% CI 0.93, 0.98), less likely to be assigned to high drug use districts (APR = 0.50, 95% CI 0.29, 0.87), more likely to believe that methadone programs reduce crime (APR = 2.43, 95% CI 1.30, 4.55), and less likely to believe that SSPs increase risk of needlestick injury for police (APR = 0.44, 0.27, 0.71). Beliefs related to the occupational impact of harm reduction services in terms of officer safety and crime reduction are associated with support for referral to related harm reduction services. Efforts to deflect PWID from carceral systems toward harm reduction by frontline police should include measures to improve officer knowledge and attitudes about harm reduction services as they relate to occupational safety and law enforcement priorities. NCT02444403.
Sections du résumé
BACKGROUND
Police constitute a structural determinant of health and HIV risk of people who inject drugs (PWID), and negative encounters with law enforcement present significant barriers to PWID access to harm reduction services. Conversely, police may facilitate access via officer-led referrals, potentiating prevention of HIV, overdose, and drug-related harms. We aimed to identify police characteristics associated with support for officer-led referrals to addiction treatment services and syringe service programs (SSP). We hypothesized that officers who believe harm reduction services are contradictory to policing priorities in terms of safety and crime reduction will be less likely to support police referrals.
METHODS
Between January and June 2018, police officers (n = 305) in Tijuana, Mexico, completed self-administered surveys about referrals to harm reduction services during the 24-month follow-up visit as part of the SHIELD police training and longitudinal cohort study. Log-binomial regression was used to estimate adjusted prevalence ratios and model policing characteristics and attitudes related to officers' support for including addiction treatment and SSP in referrals.
RESULTS
Respondents were primarily male (89%), patrol officers (86%) with a median age of 38 years (IQR 33-43). Overall, 89% endorsed referral to addiction services, whereas 53% endorsed SSP as acceptable targets of referrals. Officers endorsing addiction services were less likely to be assigned to high drug use districts (adjusted prevalence ratio [APR] = 0.50, 95% CI 0.24, 1.08) and more likely to agree that methadone programs reduce crime (APR = 4.66, 95% CI 2.05, 9.18) than officers who did not support addiction services. Officers endorsing SSPs were younger (adjusted prevalence ratio [APR] = 0.96 95% CI 0.93, 0.98), less likely to be assigned to high drug use districts (APR = 0.50, 95% CI 0.29, 0.87), more likely to believe that methadone programs reduce crime (APR = 2.43, 95% CI 1.30, 4.55), and less likely to believe that SSPs increase risk of needlestick injury for police (APR = 0.44, 0.27, 0.71).
CONCLUSIONS
Beliefs related to the occupational impact of harm reduction services in terms of officer safety and crime reduction are associated with support for referral to related harm reduction services. Efforts to deflect PWID from carceral systems toward harm reduction by frontline police should include measures to improve officer knowledge and attitudes about harm reduction services as they relate to occupational safety and law enforcement priorities.
TRIAL REGISTRATION
NCT02444403.
Identifiants
pubmed: 34311765
doi: 10.1186/s12954-021-00513-4
pii: 10.1186/s12954-021-00513-4
pmc: PMC8313001
doi:
Banques de données
ClinicalTrials.gov
['NCT02444403']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Subventions
Organisme : FIC NIH HHS
ID : R25 TW009343
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009343
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA023356
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA043421
Pays : United States
Organisme : NIDA NIH HHS
ID : DP2 DA049295
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA039073
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Soc Sci Med. 2005 Sep;61(5):1026-44
pubmed: 15955404
Harm Reduct J. 2018 May 18;15(1):27
pubmed: 29776368
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):369-76
pubmed: 18176320
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
J Int AIDS Soc. 2016 Jul 18;19(4 Suppl 3):20897
pubmed: 27435717
Int J Drug Policy. 2015 Jan;26(1):112-5
pubmed: 25239286
Health Justice. 2020 Apr 29;8(1):9
pubmed: 32350636
N Engl J Med. 2016 Jul 21;375(3):229-39
pubmed: 27468059
BMJ Open. 2015 Aug 10;5(8):e008958
pubmed: 26260350
Int J Drug Policy. 2015 Feb;26 Suppl 1:S5-11
pubmed: 25727260
Eval Program Plann. 2017 Oct;64:49-56
pubmed: 28531654
BMC Int Health Hum Rights. 2018 Sep 15;18(1):36
pubmed: 30219105
Public Health. 2021 Mar;192:8-11
pubmed: 33601307
BMC Public Health. 2017 Apr 11;17(1):309
pubmed: 28399843
BMJ Open. 2019 Jan 29;9(1):e026298
pubmed: 30700490
Int J Drug Policy. 2017 Mar;41:132-139
pubmed: 28111221
J Urban Health. 2011 Feb;88(1):104-17
pubmed: 21246301
Subst Use Misuse. 2020;55(12):1919-1924
pubmed: 32660302
Int J Epidemiol. 2014 Feb;43(1):235-48
pubmed: 24374889
Drug Alcohol Depend. 2013 Nov;132 Suppl 1:S48-52
pubmed: 23896307
Lancet HIV. 2017 Aug;4(8):e357-e374
pubmed: 28515014
MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
J Immigr Minor Health. 2019 Dec;21(6):1200-1207
pubmed: 30771144
Int J Drug Policy. 2014 Jan;25(1):105-11
pubmed: 23916801
BMJ. 2012 Oct 03;345:e5945
pubmed: 23038795
Drug Alcohol Depend. 2019 Dec 1;205:107617
pubmed: 31707271
Health Hum Rights. 2019 Jun;21(1):227-238
pubmed: 31239629
Harm Reduct J. 2018 May 23;15(1):28
pubmed: 29792191
Addiction. 2018 Jun;113(6):1056-1063
pubmed: 29333664
Am J Public Health. 2015 Jul;105(7):e5-16
pubmed: 25973818
Rev Educ Res. 2016 Jun;86(2):360-407
pubmed: 27274585
Drug Alcohol Depend. 2005 Sep 1;79(3):281-93
pubmed: 16102372
Epidemiol Rev. 2020 Jan 31;42(1):27-40
pubmed: 33184637
J Int AIDS Soc. 2014 Jul 09;17:19043
pubmed: 25014321
BMC Int Health Hum Rights. 2009 Oct 07;9:24
pubmed: 19811653
Harm Reduct J. 2014 Feb 12;11:4
pubmed: 24520885
J Urban Health. 2006 Mar;83(2):299-307
pubmed: 16736378
Nat Med. 2020 Jun;26(6):819-820
pubmed: 32555514
Harm Reduct J. 2008 Nov 20;5:36
pubmed: 19021899
J Subst Abuse Treat. 2016 Feb;61:26-33
pubmed: 26470596
Drug Alcohol Depend. 2015 Mar 1;148:221-5
pubmed: 25655577
Drug Alcohol Depend. 2018 Dec 1;193:137-141
pubmed: 30384320
BMJ Open. 2019 Dec 1;9(11):e030302
pubmed: 31791964
J Immigr Minor Health. 2009 Feb;11(1):1-6
pubmed: 18247117
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Addiction. 2016 Jul;111(7):1246-56
pubmed: 26879179
Subst Abuse Treat Prev Policy. 2020 Oct 2;15(1):75
pubmed: 33008431
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Subst Abuse Treat Prev Policy. 2016 Jan 26;11:5
pubmed: 26812913
Ann Epidemiol. 2012 Jun;22(6):426-38
pubmed: 22626001
Int J Drug Policy. 2010 Nov;21(6):459-65
pubmed: 20800464
AIDS Care. 2018 Apr;30(4):480-487
pubmed: 29067855
Drug Alcohol Rev. 2019 Feb;38(2):131-150
pubmed: 30785229
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
Int J Ment Health Addict. 2013 Feb 1;11(1):110-122
pubmed: 23956702
Am J Addict. 2018 Dec;27(8):608-611
pubmed: 30516331
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Int AIDS Soc. 2020 Oct;23(10):e25632
pubmed: 33119183
Harm Reduct J. 2015 Mar 01;12:3
pubmed: 25889589
Am J Public Health. 2019 Jun;109(6):921-926
pubmed: 30998406
J Int AIDS Soc. 2020 Jul;23(7):e25583
pubmed: 32697423
J Occup Environ Med. 2020 Jan;62(1):46-51
pubmed: 31658223
AIDS Behav. 2008 Jul;12(4):552-60
pubmed: 18369723
J Subst Abuse Treat. 2017 Nov;82:41-47
pubmed: 29021114